<DOC>
	<DOCNO>NCT01896297</DOCNO>
	<brief_summary>The goal study ass dabigatran pharmacokinetics NVAF subject severe renal impairment define creatinine clearance 15 30 mL/min calculate Cockcroft-Gault formula . The dabigatran etexilate dose 75 mg BID approve FDA NVAF patient severe renal impairment ( CrCl 15-30 mL/min ) , base pharmacokinetic modeling simulation .</brief_summary>
	<brief_title>Pradaxa Study Non-valvular Atrial Fibrillation Patients With Severely Impaired Renal Function</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Dabigatran</mesh_term>
	<criteria>Inclusion criterion : Subjects diagnose nonvalvular atrial fibrillation indication anticoagulation therapy , Subjects severe renal function impairment define creatinine clearance 15 30 mL/min CockcroftGault formula , Male female patient , age =18 year entry Exclusion criterion : Contraindications Pradaxa ( history serious hypersensitivity reaction Pradaxa , active pathological bleeding , patient mechanical prosthetic heart valve ) , Creatinine clearance &lt; 15ml/min patient End Stage Renal Disease dialysis , Creatinine clearance &gt; 30 ml/min , Premenopausal woman ( last menstruation less one year prior informed consent ) nursing pregnant , child bear potential practicing acceptable method birth control , plan continue use method throughout study . Acceptable method birth control include abstinence , tubal ligation , transdermal patch , intra uterine devices/systems ( IUDs/IUSs ) , oral , implantable injectable contraceptive , double barrier method vasectomise partner , Patients participate another drug study , Patients participate another drug study within 6 week , Patients consider unreliable investigator concern requirement participate study , include followup interview , Any condition investigator believe would allow safe participation study ,</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>